CN1461656A - Medicinal excipient-potassium alginate and its composition - Google Patents
Medicinal excipient-potassium alginate and its composition Download PDFInfo
- Publication number
- CN1461656A CN1461656A CN02109875A CN02109875A CN1461656A CN 1461656 A CN1461656 A CN 1461656A CN 02109875 A CN02109875 A CN 02109875A CN 02109875 A CN02109875 A CN 02109875A CN 1461656 A CN1461656 A CN 1461656A
- Authority
- CN
- China
- Prior art keywords
- component
- medicine
- composition
- potassium alginate
- depressor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000737 potassium alginate Substances 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims description 56
- 239000003814 drug Substances 0.000 claims abstract description 83
- 235000010408 potassium alginate Nutrition 0.000 claims abstract description 80
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims abstract description 80
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 10
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 4
- 239000000375 suspending agent Substances 0.000 claims abstract description 4
- 239000002562 thickening agent Substances 0.000 claims abstract description 3
- 239000002934 diuretic Substances 0.000 claims description 18
- 230000001882 diuretic effect Effects 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 239000002876 beta blocker Substances 0.000 claims description 9
- 229940097320 beta blocking agent Drugs 0.000 claims description 9
- 239000005541 ACE inhibitor Substances 0.000 claims description 8
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 8
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 8
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 8
- 239000000480 calcium channel blocker Substances 0.000 claims description 8
- -1 terpene lactones Chemical class 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- AIMATLPOKDHHTR-UHFFFAOYSA-N 2,2,2-trifluoro-1-thiophen-2-ylethanamine Chemical compound FC(F)(F)C(N)C1=CC=CS1 AIMATLPOKDHHTR-UHFFFAOYSA-N 0.000 claims description 4
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002911 Colestipol Polymers 0.000 claims description 4
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 4
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 4
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 4
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960003526 acipimox Drugs 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 229960000516 bezafibrate Drugs 0.000 claims description 4
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 4
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims description 4
- 229960002604 colestipol Drugs 0.000 claims description 4
- 229950009036 etofylline clofibrate Drugs 0.000 claims description 4
- 229930182486 flavonoid glycoside Natural products 0.000 claims description 4
- 150000007955 flavonoid glycosides Chemical class 0.000 claims description 4
- 229960003627 gemfibrozil Drugs 0.000 claims description 4
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 4
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 4
- 229960005436 inositol nicotinate Drugs 0.000 claims description 4
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 4
- 229960000903 pantethine Drugs 0.000 claims description 4
- 235000008975 pantethine Nutrition 0.000 claims description 4
- 239000011581 pantethine Substances 0.000 claims description 4
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003912 probucol Drugs 0.000 claims description 4
- 235000007586 terpenes Nutrition 0.000 claims description 4
- 241000218236 Cannabis Species 0.000 claims description 3
- 241000675108 Citrus tangerina Species 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 3
- 241000237636 Pheretima Species 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 210000004681 ovum Anatomy 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000661 sodium alginate Substances 0.000 abstract description 4
- 235000010413 sodium alginate Nutrition 0.000 abstract description 4
- 229940005550 sodium alginate Drugs 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 description 20
- 206010020772 Hypertension Diseases 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229960001597 nifedipine Drugs 0.000 description 6
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 239000000783 alginic acid Substances 0.000 description 5
- 229960001126 alginic acid Drugs 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000003087 receptor blocking agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000019025 Hypokalemia Diseases 0.000 description 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000024896 potassium deficiency disease Diseases 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 241000050051 Chelone glabra Species 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-ACJLOTCBSA-N (R,R)-labetalol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 SGUAFYQXFOLMHL-ACJLOTCBSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000738 Angiotensin-3 Proteins 0.000 description 1
- 102400000348 Angiotensin-3 Human genes 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000027032 Renal vascular disease Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229950010351 amosulalol Drugs 0.000 description 1
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229950010731 arotinolol Drugs 0.000 description 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical class [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960003588 bevantolol Drugs 0.000 description 1
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001035 bopindolol Drugs 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229950002568 bucumolol Drugs 0.000 description 1
- CIJVBYRUFLGDHY-UHFFFAOYSA-N bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229950009702 darodipine Drugs 0.000 description 1
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229950007942 dilevalol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002005 ganglioplegic effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229950000109 niludipine Drugs 0.000 description 1
- VZWXXKDFACOXNT-UHFFFAOYSA-N niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000015670 renal artery disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A medicinal excipient, potassium alginate, is disclosed, which can also be used as the additive, emulsifier, suspending agent, or thickening agent of medicine. A composite medicine for reducing pressure and fat of blood is prepared from potassium alginate instead of sodium alginate and other Chinese medicines and/or Western medicines. Its advantages are quickly and durably taking its effect, low dosage, and low by-effect.
Description
[technical field] the present invention relates to a kind of new drug excipient---potassium alginate and all kinds of blood pressure lowerings, the blood fat lowering composition medicine made as excipient by it.
[background technology] potassium alginate (Potassium Alginate) claims that again potassium alginate, its rational formula are (C
6H
7O
6K) n.This chemical compound has been public as food additive, but still meets reported in literature in the end as the medicine excipient.Although alginic acid, sodium alginate are done the excipient of medicine in a lot of countries, and are written into European Pharmacopoeia, in the local medicine will in American Pharmacopeia and Liaoning, owing to be subjected to traditional view constraint restriction, potassium alginate never has the people it is used as the medicine excipient.
The eighties initial stage, seen the bibliographical information that relevant potassium alginate can suppress the spontaneous hypertension white mouse hypertension effect of high sodium feed, related content is documented in the paper of a piece of the border Sargassum meeting of eight or three young island countries " 10N-EXCHANGE AND HYPOTENSIVE EFECTS OF POTASSIUNALGINATE IN RATS ON HIGH SODIUM DIET " by name.This paper is explained the blood pressure lowering mechanism of having chatted potassium alginate: in the time of in potassium alginate enters stomach, gastric acid becomes alginic acid with potassium alginate; Alginic acid enters in the intestinal at first and the sodium ion combination, along with feces is got rid of external.Animal experiment shows that the sodium excretion amount in the feed potassium alginate group rat feces is apparently higher than matched group.This blood pressure lowering mechanism is different from the depressor of present disclosed all categories, therefore can regard potassium alginate as a class novel depressor.
Relevant potassium alginate also has a lot of reports, in the CN1095307A application for a patent for invention description, discloses the marine alga food for decreasing fat that a kind of main component is oligomeric potassium alginate.It is 2～5 that the flat 6-237783A of JP discloses a kind of degree of polymerization, and molecular weight is the sour potassium in 100～1800 daltonian brown seas, and this potassium alginate only is suitable for adding to a kind of health food of preparation in the food.In the ZL96114651.6 patent documentation, disclosing a kind of viscosity is 1～20 centipoise, and molecular weight is 2000～50000 potassium alginate, mainly is used as antihypertensive drugs, health food and food.
The potassium alginate that the present invention relates to, for above-mentioned patent documentation open before promptly public chemical compound.Doing food additive during the sixties abroad uses, test according to the inventor, viscosity all has the effect of inhibition hypertension in various degree to spontaneous hypertension rat (SHR) at 40 centipoises, 60 centipoises, 80 centipoises, 120 centipoises, 150 centipoises (above viscosity data is all measured with rotary viscosity method commonly used), therefore, this document is mentioned the potassium alginate that potassium alginate is a general reference, is not subjected to keeping within bounds of above-mentioned patent documentation.
The report of alginic acid, alginate (comprising potassium alginate) blood fat reducing also begins to see the sixties, the inventor utilizes the SD rat test, finds that viscosity all has the trend that SD rat plasma cholesterol levels and triglyceride level are reduced at the potassium alginate of 10,20,40,80,120,150 centipoises (these data all record with the rotary viscosity method).
Yet, how to make this natural ocean blood pressure lowering of potassium alginate, blood fat reducing active substance be able to better application, thereby it is faster to obtain onset, better effects if, safety is higher, side effect still less, more economical, the convenient blood pressure lowering of using, the blood fat reducing medicine.The inventor has done a large amount of formula combination and experimental study to this, find that therefrom potassium alginate can participate in the prescription with two kinds of identity, and a kind of is the medicine excipient; A kind of is new depressor.This hypotensor, the inventor is referred to as the depressor of " digestive tract row sodium class ".
[summary of the invention] the objective of the invention is to overcome the deficiency of above-mentioned prior art and a kind of drug excipient is provided---potassium alginate and composition of medicine thereof.
Above-mentioned purpose of the present invention is accomplished by following technological means.
A kind of drug excipient can use as adjuvant, emulsifying agent, suspending agent, thickening agent in preparation, it is characterized in that said drug excipient is a potassium alginate, and its rational formula is (C
6H
7O
6K) n.This excipient can adopt the potassium alginate of any molecular weight section, any range of viscosities, makes various Western medicine preparations and Chinese medicine preparation with any medicament mixed.
The toxicological study of relevant potassium alginate; national public health of Holland and environmental conservation institute toxicologic study chamber; existing penetrating elaboration the before 30 years drafted in the 17 meeting that ADI value is that per kilogram of body weight 50mg (in alginic acid) as seen is very safe material in the food.Discriminating item in study of pharmacy and inspection item, comprising transparency, sulfate, loss on drying, residue on ignition, heavy metal, the chemical examination of arsenic salt item prove the complete conformance with standard of potassium alginate.Do the tablet of adjuvant with potassium alginate, the test of disintegration also meets the requirements fully.
In sum, illustrate that potassium alginate is a kind of complete satisfactory medicine excipient.
A kind of composition of medicine that contains above-mentioned potassium alginate excipient component is characterized in that containing in the said composition of medicine depressor component, and this depressor is the beta-blocker component; Or/and calcium antagonist component; Or/and angiotensin converting enzyme inhibitor component; Or/and vasodilator component; Or/and a kind of or more than one combination in any of diuretic component, the weight of above-mentioned depressor component is 0.001%～100% of potassium alginate composition weight.
A kind of composition of medicine that contains said components; it is characterized in that containing in the said composition of medicine Chinese medicine depressor; this depressor be Pheretima, Radix Scutellariae, Radix Aristolochiae, one or more of bone, Herba Plantaginis, trailing plants cloth Folium Cannabis, green tangerine, Herba Leonuri, Calculus Bovis, Margarita, Flos Chrysanthemi component form Chinese traditional compound medicines, the weight of above-mentioned depressor component is 1%～200% of potassium alginate composition weight.
A kind of composition of medicine that contains said components, it is characterized in that containing in the said composition of medicine lipid lowerers component, this lipid lowerers is to examine rare amine, colestipol, the Lip river is cut down him and is ordered, generally cut down him and order, plug cuts down him and orders, probucol, nicotinic acid, inositol niacinate, acipimox, the chloroethene spy, bezafibrate, Etofylline Clofibrate, non-unconcerned Bei Te, gemfibrozil, pantethine, or active skull cap components ovum phosphoric acid, polyenoic acid, one or more combination in any of Ginkgo biloba extract (flavonoid glycoside and terpene lactones) component, the weight of above-mentioned lipid lowerers component is 0.001%～100% of potassium alginate composition weight.
According to country's " drug approval way " regulation, the acidic group of medicine is changed into sodium salt or potassium salt or changes a kind of sodium salt of medicine into potassium salt, should treat by similar medicine.Sodium alginate and potassium alginate belong to the sodium salt and the potassium salt of alginic acid together, and the excipient that therefore is equivalent to be identified can be done the adjuvant, excipient, emulsifying agent, suspending agent, ropiness increasing agent of preparation etc.Therefore, potassium alginate can be made various dosage forms with any medicament mixed.The present invention utilizes potassium alginate to substitute traditional sodium alginate as drug excipient, not only can play kalium replenishment row sodium effect to human body, and can utilize the blood pressure lowering mechanism of potassium alginate, with all kinds of Western medicine preparations or the mutual compatibility of Chinese medicine preparation, make blood pressure lowering, the blood fat lowering composition medicine of newtype.The above-mentioned composition of medicine that contains the potassium alginate component, compare with one-component potassium alginate medicine, have advantages such as drug effect is fast, dosage is little, drug action is lasting, the present invention has overcome in the prior art simple with the shortcoming that potassium alginate is slow as the existing onset of antihypertensive drugs, taking dose is big, and can alleviate the toxic and side effects of existing Western medicine preparation or Chinese medicine preparation simultaneously.This potassium alginate participates in pharmaceutical formulation as excipient and has dual function, and the combined therapy effect obviously improves, and safety is reliable.
[specific embodiment] embodiment one: make composition of medicine with depressor and potassium alginate, the depressor composition weight that contains in this composition of medicine is 0.005%～60% of a potassium alginate composition weight.Above-mentioned depressor can adopt beta-blocker, but as the standing clinical depressor propranolol hydrochloride of present use, timolol maleate, for comet Luo Er, nadolol, sotalol, bopindolol, bucumolol, A Leiluoer, 7-[2-hydroxy-3-(isopropylamino)propoxy, fluorine Luo Er, bevantolol, plug ground Luo Er, bisoprolol, Tartaric acid metoprolol, alprenolol, times Ta Leer, esmolol, acebutolol, amosulalol, labetalol, dilevalol, arotinolol, Carvedilol, Celiprolol.
Beta-blocker side effect and untoward reaction be usually as seen: anxious, neurotic, maincenter depression, dreaminess, illusion, vomiting, headache, cardiopalmus, tachycardia, weak, tremble, perspiration, anorexia, feel sick, stomachache, vomiting, serious hypertension.
The blood pressure lowering mechanism of beta-blocker is optionally to combine with beta receptor in the adrenoceptor, hinders the noradrenergic nerve mediator to combine with beta receptor, the generation adrenolytic.Cardiac insufficiency, asthma, peripheral blood vessel spasm, hypoglycemia, bradycardia, the careful usefulness of atrioventricular block person.
Make composition of medicine with above-mentioned any one or more than one beta-blocker and potassium alginate, the beta-blocker depressor composition weight that contains in this composition of medicine is 0.001%～10% of a potassium alginate composition weight, can obviously reduce the side effect of beta-blocker depressor component.
Embodiment two, and clinical normal selection diuretic and B-receptor blocking agent share, to alleviate the hypokalemia that some diuretic is caused.Clinical trial, the patient who takes metoprolol adds potassium alginate, antihypertensive effect more than single much better with one side, can improve sleep state significantly, and dreaminess, illusion, symptom such as anxious also obviously weaken.Take 100 milligrams of diuretic and B-receptor blocking agents former every day, can change into and take 50 milligrams every day, potassium alginate is to take 3 gram amounts every day by taking 6～8 gram quantitative changes every day.The part by weight configuration arbitrarily of diuretic and B-receptor blocking agent.
Conclusion: still put into practice from theory and to verify that all potassium alginate can use with diuretic and B-receptor blocking agent compatibility.Characteristics: to the remarkable blood pressure lowering blood pressure of hypertensive patient, do not cause orthostatic hypotension and electrolyte disturbance, the follow-up continuation of insurance of drug withdrawal maintained an equal level steady blood pressure 4-6 days, obviously alleviated epigastric discomfort, asthenia and parahypnosis etc.
Embodiment three: calcium antagonist is the very potential depressor of a class, calcium antagonist commonly used at present has nifedipine, nicardipine, nitrendipine, nimodipine, amlodipine, niludipine, isradipine, Buddhist nun's comet Horizon, Felodipine, darodipine, SKF-102362, Manidipine, lacidipine, benidipine, barnidipine etc.
The blood pressure lowering mechanism of above-mentioned calcium antagonist is to suppress calcium ion to stride in the film stream and influence calcium ion and act in cell, and the medicine that whole cell function is changed, free calcium ion concentration descends in blood vessel wall and the myocardial cell slurry because it can make, myocardial contraction weakens and is the negativity muscular strength and uses, reduce cardiac muscle power consumption oxygen consumption, expansion peripheral vessels, blood pressure reduce, and cardiac load alleviates.
Take the common side effect of calcium antagonist headache, dizziness, erubescence, hypotension, numb limbs and tense tendons, nausea and vomiting, weak etc. are arranged.
Clinical trial, nifedipine and potassium alginate are used, and can obtain windfall effect.
1, side effect obviously alleviates, the original numb limbs and tense tendons of patient, feel sick, vomiting, anesthesia such as weak, the headache and dizzy symptom is improved, should should be mentioned that especially, some male patient takes calcium ion antagonist for a long time such as nifedipine (nifedipine), Norvasc (amlodipine) etc. can cause sexual hypofunction even forfeiture, and after being used with potassium alginate, sexual function can be restored.
2, can obtain rapid-actionly, not have the effect of bounce-back, after the drug withdrawal, can keep 4～5 days blood pressure lowering state, go up gradually after the week, see following one group of data (mmHg of blood pressure unit):
| Time | Before taking | 24 hours | 2 weeks | 4 weeks | After the drug withdrawal 2 days | After the drug withdrawal 4 days |
| Swelling pressure relaxes | 102 | 92 | 85 | 83 | 86 | 90 |
| Systolic pressure | 185 | 150 | 140 | 132 | 135 | 142 |
Annotate: be the meansigma methods of test group n=12.
3, make the dosage of nifedipine and potassium alginate be reduced to half amount respectively.
Patient's folk prescription is taken four of 10mg sheet nifedipines every day; Folk prescription is taken potassium alginate (water content 15%) every day needs 6～8 gram/skies.After both share, nifedipine two meters every day 20mg, potassium alginate gram every days 3.
4, the lipid level of having a blood test after the treatment, T-CHOL and triglyceride level all are significant reduction.
Make composition of medicine with above-mentioned any one or more than one calcium antagonist and potassium alginate, this composition of medicine can make up with the foregoing description, forms new compound recipe Chinese-western medicine preparation.
Embodiment four: potassium alginate and angiotensin converting enzyme inhibitor combination.
Angiotensin converting enzyme inhibitor is the emerging rising depressor of a class, commonly used captopril, enalapril, alacepril, thunder end Puli, quinapril, delapril hydrochloride, cilazapril, benazepril, TA-6366 is arranged, accompanies diindyl Puli etc.
Blood pressure lowering mechanism: feritin is a kind of proteolytic enzyme, and it is former to be secreted into the vasoconstriction that liver is produced behind the blood---a kind of feritin substrate of alpha globulin is cracked into the angiotensin I of decapeptide.After conversion enzyme (kininase) effect, generate Angiotensin II and III, Angiotensin II can promote the synthetic release of aldosterone, angiotensin converting enzyme inhibitor ACEI suppresses the generation of Ang II, thereby suppressing kassinin kinin brings high blood pressure down, hypertension by due to the renal vascular disease all responds to ACEI, and general essential hypertension 60-70% has the blood pressure lowering reaction.This hypotensor is less than the depressor side effect of other classification, common having choke cough, erythra, heating etc.Angiotensin converting enzyme inhibitor is many to be share with diuretic, makes effectiveness strengthen, reduce hypokalemia due to the latter, and diuretic can reduce blood volume, increase Na
+Drain, the two is used, total effective rate can reach 80-85%.Make composition of medicine with above-mentioned any one or more than one angiotensin converting enzyme inhibitor and potassium alginate, this composition of medicine can make up with the foregoing description, forms new compound recipe Chinese-western medicine preparation.
Clinical trial: select primary hypertension patient 32 people, by age, after the pairing of the sex and the state of an illness, be divided into two groups at random, every group 16 people, take for one group and take 3 of captopril (formal name used at school captopril) 20mg sheet every days, another group 1.5 of captopril 20mg sheet every days, potassium alginate 3-4 every day gram, experimental result sees the following form:
Annotate: the mmHg of blood pressure unit is effective, obvious effective rate is evaluated standard rating with depressor
Embodiment five: potassium alginate and vasodilator combination
A lot of classes are arranged in the vasodilator: because the energy blood vessel dilating weakens the blood circulation Peripheral resistance, cardiac load alleviates, blood pressure drops.Common have a following kind: 1) directly act on the vascular smooth muscle medicated bag and draw together the hydralazine of expansion artery, the Yin handkerchief peace of rattling away; The nitre Pu Na of expansion artery and vein; Expansion of veins.2) α beta blocker.3) ganglioplegic.4) calcium antagonist.5) angiotensin converting enzyme inhibitor.6) blocade such as reserpine behind the intersection neuroganglion.7) other.Wherein 4), 5) narrating specially before this.
Each classification of the common adverse effect of this type of medicine is had nothing in common with each other again, with blocker reserpine behind the intersection neuroganglion, this type of drug effect is slow, the amplitude that blood pressure reduces is also undesirable, but this hypotensor is safe and reliable, reserpine is used for FUFANG JIANGYA PIAN decades, is hyperpietic's medicine commonly used so far, and xerostomia, nasal obstruction phenomenon can appear in user once in a while.
FUFANG JIANGYA PIAN is equipped with diuretic, anti-allergic drug and multivitamin and forms based on reserpine, if reserpine and potassium alginate compatibility are used, antihypertensive effect obviously strengthens.Make composition of medicine with above-mentioned any one or more than one vasodilator and potassium alginate, this composition of medicine can make up with the foregoing description, forms new compound recipe Chinese-western medicine preparation.
The characteristics of this compound recipe Chinese-western medicine preparation are: rapid depressurization, do not rebound, untoward reaction and side effect be little.
Embodiment six: potassium alginate and diuretic combination
Diuretic generally is not listed in the depressor scope in classification, take but middle effect diuretic thiazide is commonly used for depressor, and the depressor compatibility of normal and other class uses.
Mention above, mainly at digestive tract row sodium, diuretic then is to act on ascending thick limb of Henle's loop to potassium alginate, influences Na
+, CI
-Active transport, thereby be loop diuretic again.
Potassium alginate and diuretic drug combination can improve the hypokalemia that is caused by diuretic, from medullary loop and the two-way row's sodium of digestive tract, can strengthen antihypertensive effect.Make composition of medicine with above-mentioned diuretic and potassium alginate, the diuretic composition weight that contains in this composition of medicine is 0.001%～50% of a potassium alginate composition weight.
Embodiment seven: potassium alginate and the combination of other depressor
The depressor of other type such as cental system depressor etc. can make up with potassium alginate.The cental system depressor composition weight that contains in this composition of medicine is 0.002%～80% of a potassium alginate composition weight.Present embodiment can make up with the foregoing description, forms new compound recipe Chinese-western medicine preparation.
Embodiment eight: potassium alginate and the Chinese medicine composition that hypotensive effect is arranged
Some Chinese medicine has hypotensive effect, as Pheretima, Radix Scutellariae, Radix Aristolochiae, bone, Herba Plantaginis, trailing plants cloth Folium Cannabis, green tangerine, Herba Leonuri, Calculus Bovis, Margarita, Flos Chrysanthemi etc.One or more of above Chinese medicine all can with the potassium alginate compatibility, form new Chinese traditional compound medicine.The Chinese medicine depressor composition weight that contains in this composition of medicine is 30%～80% of a potassium alginate composition weight.Present embodiment can make up with the foregoing description, forms new compound recipe Chinese-western medicine preparation.
Embodiment nine: potassium alginate and lipid lowerers combination.
Lipid lowerers commonly used examine come rare amine, colestipol, Lip river cut down he order, general cut down he order, fill in cut down that he orders, probucol, nicotinic acid, inositol niacinate, acipimox, chloroethene spy, bezafibrate, Etofylline Clofibrate, non-unconcerned Bei Te, gemfibrozil, pantethine component any one or more than one.The lipid lowerers composition weight that contains in the combinations thereof medicine is 0.005%～99% of a potassium alginate composition weight.
Embodiment ten: potassium alginate and the active skull cap components that effect for reducing fat is arranged, and as polyenoic acid, lecithin, the combination of Ginkgo biloba extract (flavonoid glycoside and terpene lactones) component any one or more than one.Contain natural blood fat reducing active component in this composition of medicine, weight is 10%～70% of potassium alginate composition weight.
Claims (5)
1, a kind of drug excipient can use as adjuvant, emulsifying agent, suspending agent, thickening agent in preparation, it is characterized in that said drug excipient is a potassium alginate, and its rational formula is (C
6H
7O
6K) n.
2, a kind of composition of medicine of excipient component according to claim 1 that contains is characterized in that containing in the said composition of medicine depressor component, and this depressor is the beta-blocker component; Or/and calcium antagonist component; Or/and angiotensin converting enzyme inhibitor component; Or/and vasodilator component; Or/and a kind of or more than one combination in any of diuretic component, the weight of above-mentioned depressor component is 0.001%～100% of potassium alginate composition weight.
3, a kind of composition of medicine of excipient component as claimed in claim 1 or 2 that contains; it is characterized in that containing in the said composition of medicine Chinese medicine depressor; this depressor be Pheretima, Radix Scutellariae, Radix Aristolochiae, one or more of bone, Herba Plantaginis, trailing plants cloth Folium Cannabis, green tangerine, Herba Leonuri, Calculus Bovis, Margarita, Flos Chrysanthemi component form Chinese traditional compound medicines, the weight of above-mentioned depressor component is 1%～200% of potassium alginate composition weight.
4, a kind of composition of medicine of excipient component as claimed in claim 1 or 2 that contains, it is characterized in that containing in the said composition of medicine lipid lowerers component, this lipid lowerers is to examine rare amine, colestipol, the Lip river is cut down him and is ordered, generally cut down him and order, plug cuts down him and orders, probucol, nicotinic acid, inositol niacinate, acipimox, the chloroethene spy, bezafibrate, Etofylline Clofibrate, non-unconcerned Bei Te, gemfibrozil, pantethine, or natural blood fat reducing active component polyenoic acid, ovum phosphoric acid, one or more combination in any of Ginkgo biloba extract (flavonoid glycoside and terpene lactones) component, the weight of above-mentioned lipid lowerers component is 0.001%～100% of potassium alginate composition weight.
5, composition of medicine according to claim 3, it is characterized in that containing in the said composition of medicine lipid lowerers component, this lipid lowerers is to examine rare amine, colestipol, the Lip river is cut down him and is ordered, generally cut down him and order, plug cuts down him and orders, probucol, nicotinic acid, inositol niacinate, acipimox, the chloroethene spy, bezafibrate, Etofylline Clofibrate, non-unconcerned Bei Te, gemfibrozil, pantethine, or natural blood fat reducing active component polyenoic acid, ovum phosphoric acid, one or more combination in any of Ginkgo biloba extract (flavonoid glycoside and terpene lactones) component, the weight of above-mentioned lipid lowerers component is 0.001%～100% of potassium alginate composition weight.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02109875A CN1461656A (en) | 2002-05-28 | 2002-05-28 | Medicinal excipient-potassium alginate and its composition |
| AU2003236177A AU2003236177A1 (en) | 2002-05-28 | 2003-05-06 | Potassium alginate as pharmaceutical excipient and compositions thereof |
| PCT/CN2003/000326 WO2003099335A1 (en) | 2002-05-28 | 2003-05-06 | Potassium alginate as pharmaceutical excipient and compositions thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02109875A CN1461656A (en) | 2002-05-28 | 2002-05-28 | Medicinal excipient-potassium alginate and its composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1461656A true CN1461656A (en) | 2003-12-17 |
Family
ID=29555545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02109875A Pending CN1461656A (en) | 2002-05-28 | 2002-05-28 | Medicinal excipient-potassium alginate and its composition |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1461656A (en) |
| AU (1) | AU2003236177A1 (en) |
| WO (1) | WO2003099335A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1769303B (en) * | 2004-11-02 | 2010-08-25 | 谭攸恒 | Middle,high molecular weight potassium alginate and its compositions |
| CN101104649B (en) * | 2006-07-12 | 2011-05-18 | 谭攸恒 | Potassium alginate and composition thereof |
| WO2014190935A1 (en) * | 2013-05-30 | 2014-12-04 | 苏州科景生物医药科技有限公司 | Multi-functional composition and preparation method and application thereof |
| CN113244339A (en) * | 2021-06-04 | 2021-08-13 | 南京厚生药业有限公司 | Cholestyramine powder for hyperlipidemia and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5871447B2 (en) * | 2007-11-30 | 2016-03-01 | 花王株式会社 | GIP secretion inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097307A (en) * | 1993-07-16 | 1995-01-18 | 青岛海洋大学 | Marine alga food for decreasing fat |
| CN1081194C (en) * | 1996-12-18 | 2002-03-20 | 谭攸恒 | Process for preparing potassium alginate and its use |
-
2002
- 2002-05-28 CN CN02109875A patent/CN1461656A/en active Pending
-
2003
- 2003-05-06 WO PCT/CN2003/000326 patent/WO2003099335A1/en not_active Application Discontinuation
- 2003-05-06 AU AU2003236177A patent/AU2003236177A1/en not_active Abandoned
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1769303B (en) * | 2004-11-02 | 2010-08-25 | 谭攸恒 | Middle,high molecular weight potassium alginate and its compositions |
| CN101104649B (en) * | 2006-07-12 | 2011-05-18 | 谭攸恒 | Potassium alginate and composition thereof |
| WO2014190935A1 (en) * | 2013-05-30 | 2014-12-04 | 苏州科景生物医药科技有限公司 | Multi-functional composition and preparation method and application thereof |
| GB2529962A (en) * | 2013-05-30 | 2016-03-09 | Suzhou Sciscape Bio Pharmaceutical Technology Co Ltd | Multi-functional composition and preparation method and application thereof |
| GB2529962B (en) * | 2013-05-30 | 2017-11-22 | Suzhou Sciscape Bio-Pharmaceutical Tech Co Ltd | Composition Comprising Marine-Algae Derived Material and an Inhibitor of an Enzyme which Decomposes the Material |
| US9937198B2 (en) | 2013-05-30 | 2018-04-10 | Pinghu Sciscape Bio-Pharmaceutical Technology Co., Ltd. | Multi-functional composition and preparation method and application thereof |
| CN113244339A (en) * | 2021-06-04 | 2021-08-13 | 南京厚生药业有限公司 | Cholestyramine powder for hyperlipidemia and preparation method thereof |
| CN113244339B (en) * | 2021-06-04 | 2021-09-24 | 南京厚生药业有限公司 | Cholestyramine powder for hyperlipidemia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003099335A1 (en) | 2003-12-04 |
| AU2003236177A1 (en) | 2003-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105395577B (en) | A kind of anti-trioxypurine composition and its preparation | |
| KR20110027717A (en) | Composition comprising 1,3/1,6 beta glucan for reducing weight | |
| CN1164297C (en) | Method for preventing and curing diseases by using kakonein preparation | |
| CN102008710B (en) | Lisinopril-containing compound preparation for treating hypertension | |
| CN100475254C (en) | Anti-fatigue resistibility capsules for improving body immunity and method for making same | |
| CN1876049A (en) | An externally applied powder for treating infant diarrhea | |
| CN1461656A (en) | Medicinal excipient-potassium alginate and its composition | |
| CN104758451A (en) | Traditional Chinese medicine composite for treating gout | |
| CN1989990A (en) | Medicine for treating erection dysfunction and preparation method thereof | |
| CN1301544A (en) | Medicinal composition for curing arthritis and osteoarthropathy and its preparing method | |
| CA1208132A (en) | Composition for relieving toothache pain and other forms of intense pain | |
| CN101104649B (en) | Potassium alginate and composition thereof | |
| CN1272030C (en) | Chinese traditional medicine for treating pain of neck, shoulder, waist and leg and preparation method thereof | |
| CN1957965A (en) | Chinese traditional medicine preparation for treating impotence, and preparation method | |
| CN1440287A (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and automatic neuropathies | |
| CN1861099B (en) | Snake oil soft capsule | |
| CN1115663A (en) | Medicine for curing hypertension | |
| CN1839882A (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN104434920B (en) | A kind of pharmaceutical composition treating heart failure and application thereof | |
| CN1593562A (en) | Ginkgo leaf extract composition | |
| CN1463192A (en) | Herb compsns. for treating dopy and agrypnia | |
| CN1102407C (en) | Antidepressive capsule and preparing process thereof | |
| CN1769303B (en) | Middle,high molecular weight potassium alginate and its compositions | |
| CN1177592C (en) | Myocarditis treating medicine | |
| CN103705529A (en) | Combined resistance injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |